DENVER, July 19, 2017 -- Already regarded as one of the fastest growing and most trusted cannabidiol brands in the world, Elixinol announces expansion into Europe.
Photos accompanying this announcement are available at:
http://www.globenewswire.com/NewsRoom/AttachmentNg/9918871c-5c3d-4974-8039-2c687211b538
http://www.globenewswire.com/NewsRoom/AttachmentNg/187d5574-95f9-40d9-8e22-061d660fd2a6
http://www.globenewswire.com/NewsRoom/AttachmentNg/0978ad48-d660-4b86-b161-e457289c8402
http://www.globenewswire.com/NewsRoom/AttachmentNg/21045979-c22e-488c-8084-fdaaefb284a4
Seven Elixinol hemp oil CBD products will be available to consumers throughout Europe including best-sellers such as Liposomes, noted for their great taste and increased bioavailability, the targeted topical Rescue Balm, and CBD capsules.
Consumers throughout the world use Elixinol’s CBD hemp oil for both lifestyle improvement and condition treatment. Elixinol expects Europeans will embrace CBD hemp oil products as part of an overall wellness regimen.
“Faced with shrinking healthcare budgets and an increased emphasis on well-being, European consumers are looking for ways to get better rest, reduce stress and optimize their fitness efforts,” said Husong.
With increasing numbers of consumers in Europe embracing fitness, organic foods and stress reduction, Elixinol’s market entry meets the needs of the growing marketplace.
According to Statista, over 52% of Western Europeans rated their own health knowledge as sufficient or excellent, “translating into greater understanding of health measures and what individuals should do to improve their own health.” The health and wellness market value in Western Europe is already over 145 million euros with more growth projected. Western Europe’s dietary supplement market is projected to reach over 5.6 million euros by 2020.
“From executives who crave increased focus and stress reduction to fitness aficionados seeking faster recovery, since we launched, sales in Europe have exceeded our aggressive expectations,” said Chris Husong, Director of Global Marketing and Sales for Elixinol.
“Hemp and its benefits are nothing new for Europeans,” said Marco Cappiello, Director of European Operations for Elixinol. “But with concerns over serving size, potency and purity now addressed by Elixinol’s rigorous and transparent testing process, Europeans can now purchase CBD hemp oil with confidence,” he continued.
To eliminate consumer concerns about metals, solvents, pesticides as well as potency and purity, Elixinol is the only global brand to post independent laboratory test results online and follows a strict pharmaceutical-grade testing process.
Elixinol will source its European CBD from existing relationships with Northern European organic farmers who have been cultivating hemp for generations.
“It’s as if we’re coming home,” said Husong. “We’ve had relationships in Europe since our inception, being able to deliver the end product to the European consumer is incredibly satisfying.”
Elixinol products are available to customers in Europe on elixinol.com and in various retail health outlets throughout Spain and Italy.
About Elixinol:
Colorado-based Elixinol, founded by Paul Benhaim, hemp entrepreneur since 1991, is widely regarded as one of the most influential CBD brands in the world. With a proven track record of growing and manufacturing high-quality hemp, Elixinol also conducts rigorous laboratory testing and quality control. A global leader in hemp distribution, Elixinol distributes CBD products in 22 countries globally including United States, Japan, Puerto Rico, Brazil and throughout Europe. More information available at Elixinol.com.
Photos may also be available via AP PhotoExpress.
Media Contact: Chris Husong Elixinol +1 844-804-3504 ext 420 [email protected]


Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Apple Turns 50: From Garage Startup to AI Crossroads
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 



